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Methods: Adult participants with virologic suppression (plasma
HIV-1 RNA ,50 copies/mL) were randomized (1:1) to continue
with their current antiretroviral regimen (CAR) or switch to the long-
acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In
the LA arm, participants initially received oral CAB + RPV once-
daily for 4 weeks to assess individual safety and tolerability, before
starting monthly injectable therapy. The primary endpoint of this
combined analysis was antiviral efficacy at week 48 (FDA Snapshot
algorithm: noninferiority margin of 4% for HIV-1 RNA $50
copies/mL). Safety, tolerability, and confirmed virologic failure (2
consecutive plasma HIV-1 RNA $200 copies/mL) were
secondary endpoints.
Results: The pooled intention-to-treat exposed population included
591 participants in each arm [28% women (sex at birth), 19% aged
$50 years]. Noninferiority criteria at week 48 were met for the
primary (HIV-1 RNA $50 copies/mL) and key secondary (HIV-1
RNA ,50 copies/mL) efficacy endpoints. Seven individuals in each
arm (1.2%) developed confirmed virologic failure; 6/7 (LA) and 3/7
(CAR) had resistance-associated mutations. Most LA recipients (83%)
experienced injection site reactions, which decreased in incidence over
time. Injection site reactions led to the withdrawal of 6 (1%)
participants. The serious adverse event rate was 4% in each arm.
Conclusion: This combined analysis demonstrates monthly
injections of CAB + RPV LA were noninferior to daily oral
CAR for maintaining HIV-1 suppression.
KeyWords: long-acting, antiretroviral therapy, injectable, cabotegravir,
rilpivirine, HIV
(J Acquir Immune Defic Syndr 2020;85:498–506)
INTRODUCTION
HIV remains a major global health concern, with the
Joint United Nations Programme on HIV/AIDS and the
World Health Organization (WHO) estimating the number
of people living with HIV (PLWH) to be ;37.9 million in
2018.1,2 Improvements in HIV treatment efficacy are reflected
in the increases in longevity of PLWH.3 Despite this progress,
the effectiveness of current antiretroviral therapy (ART) is
challenged by the need to maintain high levels of adherence
to sustain virologic suppression.4 Factors related to regimen
complexity, such as dosing frequency and pill burden, food
considerations, stigma, and drug–drug interactions between
oral antiretrovirals and commonly prescribed non-ART
medications, are reported to contribute to this challenge.4–6
Furthermore, the emotional burden of living with HIV may be
compounded by daily oral pill taking and additional com-
plexities.7 Therefore, there is considerable interest in devel-
oping long-acting (LA) treatments that can address many of
these issues while simplifying ART for PLWH.8
The recommended ART regimen for PLWH generally
consists of daily doses of either an oral 2-drug or 3-drug
combination.9,10 This combination typically involves an
integrase strand transfer inhibitor (INSTI) (dolutegravir as
the sole INSTI preferred for use in adults in the WHO
guidelines9 and either dolutegravir, bictegravir, or raltegravir
preferred in the US Department of Health and Human
Services guidelines10), in combination with 2 nucleoside
reverse transcriptase inhibitors (NRTIs); although, a single
NRTI (lamivudine) in combination with dolutegravir has
recently been recommended as a 2-drug regimen in HIV
treatment guidelines.10
Cabotegravir (CAB) (GSK1265744) is an investigational
INSTI and structural analog of dolutegravir.11 Rilpivirine
(RPV) is a next-generation non-NRTI (NNRTI) currently
approved as a once-daily oral tablet to be used in combination
with other antiretrovirals for the treatment of HIV infec-
tion.12,13 Both compounds are formulated as LA agents to be
administered intramuscularly (IM), with oral formulations of
RPV and a new formulation of CAB in development.13 These
oral formulations have been used during an oral lead-in phase
in the ATLAS14 and FLAIR15 studies to assess safety and
tolerability before study participants transitioning to LA
therapy with CAB and RPV. This 2-drug oral combination
therapy of CAB and RPV was assessed in the LATTE
(NCT01641809) study and shown to provide similar antiviral
activity compared with efavirenz plus dual NRTIs.16
A single IM injection of CAB LA 800 mg or RPV LA
1200 mg demonstrated sustained mean or geometric mean
plasma concentrations above their respective in vitro protein-
adjusted 90% inhibitory concentrations (PA-IC90) at 32 weeks
postdose for CAB LA17 (PA-IC90 0.166 mg/mL), and 24 weeks
postdose for RPV LA18 (PA-IC90 12 ng/mL), providing
rationale to investigate the 2 drugs as an LA combination
regimen. In the LATTE-2 (NCT02120352) randomized, open-
label phase 2b clinical trial, the injectable LA combination of
CAB and RPV (CAB + RPV LA) as a 2-drug HIV-1
maintenance therapy, administered every 4 or 8 weeks, was
similar to daily 3-drug oral therapy of CAB plus abacavir/
lamivudine in maintaining viral suppression (plasma HIV-1
RNA ,50 copies per/mL; FDA Snapshot algorithm) through
96 weeks.19 Together, these results supported phase 3 investi-
gation of CAB + RPV LA.
ATLAS (NCT02951052)14 and FLAIR (NCT02938520)15
are ongoing randomized, open-label, multinational phase 3
studies. These studies demonstrated that monthly injections of
CAB + RPV LA were noninferior based on the primary endpoint
(participants with plasma HIV-1 RNA $50 copies/mL at week
48) compared with a control group who continued their oral
current antiretroviral regimen (CAR). The individual results of
these studies are published elsewhere.14,15 Here, we present the
preplanned pooled analyses of the efficacy (noninferiority), viral
resistance, pharmacokinetic analysis, safety and tolerability, and
preference findings observed in participants enrolled in the
ATLAS and FLAIR studies.
METHODS
Study Design and Participants
ATLAS (NCT02951052) and FLAIR (NCT02938520)
are randomized, multicenter, parallel-group, open-label phase
3 studies comparing CAB + RPV LA with CAR in ART-
experienced PLWH-1 infection. Both studies comprised a
screening phase, maintenance phase, and extension phase;
participants in the FLAIR study initially received an induction
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antiretroviral regimen to achieve viral suppression before the
maintenance phase (Fig. 1A). Details of the respective study
designs are reported elsewhere.14,15
Enrolled study participants were $18 years old, or
$19 years where required by local regulations. In the FLAIR
study, all participants received an initial fixed-dose oral
regimen of 600 mg abacavir, 50 mg dolutegravir, and
300 mg lamivudine once-daily for 20 weeks before random-
ization (non-abacavir–based backbone was administered for
participants positive for HLA-B*5701, and an alternative
backbone was chosen for those intolerant to or who developed
toxicity to any component of the backbone regimen). Partic-
ipants with suppressed plasma HIV-1 RNA (,50 copies/mL)
in both studies were randomized (1:1) to receive either CAB +
RPV LA monthly IM injections or to continue their daily CAR.
Randomization was stratified by: sex at birth and baseline HIV-
FIGURE 1. Study design and partic-
ipant disposition. A, Study design.
*Uninterrupted ART 6 months and VL
,50 copies/mL at screening, 2 · VL
,50 copies/mL #12 months
(1 within the 6–12-month window,
and 1 within 6 months prior to
screening). †Optional switch to CAB +
RPV LA at week 52 for those on CAR.
‡Participants received an initial load-
ing dose of CAB LA (600mg) and RPV
LA (900 mg) at week 4. From week 8
onward, participants received CAB LA
(400 mg) + RPV LA (600 mg) injec-
tions every 4 weeks. §The presence of
any major INSTI or NNRTI resistance-
associated mutation (except K103N)
from prior genotype assay results
were exclusionary. Figure adapted
from Murray M, Antela A, Mills A, et
al. Patient-Reported Outcomes in
ATLAS and FLAIR Participants
on Long-Acting Regimens of Cabo-
tegravir and Rilpivirine Over 48
Weeks. AIDS Behav. 2020. https://
doi.org/10.1007/s10461-020-02929-
8, under a Creative Commons Attri-
bution 4.0 International License, http://
creativecommons.org/licenses/by/4.0/.
3TC, lamivudine; ABC, abacavir; CAB,
cabotegravir; CAR, current anti-
retroviral therapy; DTG, dolutegravir;
IM, intramuscular; HBsAg, hepatitis B
surface antigen; PI, protease inhibitor;
RAM, resistance-associated mutation;
RPV, rilpivirine; VL, viral load. B,
Participant disposition. *Participants
who completed study participation at
week 52 had the option to continue
by entering the extension phase,
transitioning to the ATLAS-2M study,
or leaving the study (no withdrawal
visit needed). The latter was not cap-
tured in this figure. ‡The remaining
65 participants in FLAIR were with-
drawn from the study prior to ran-
domization into the maintenance
phase. CAR, current antiretroviral
therapy; CAB, cabotegravir; RPV,
rilpivirine.
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1 RNA (,100,000 or$100,000 copies/mL) for FLAIR; sex at
birth and baseline regimen third-agent class (protease inhibitor,
INSTI, or NNRTI) for ATLAS. Participants in the LA arm
received oral CAB + RPV until week 4 or longer (oral lead-in)
before switching to the IM regimen. Oral therapy (bridging)
with CAB + RPV was available for participants who were
unable to make a scheduled visit within the injection window.
Participants with confirmed virologic failure (CVF; 2
consecutive plasma HIV-1 RNA measurements
$200 copies/mL) were discontinued from the study treat-
ment. Participants who withdrew from LA therapy entered
long-term follow-up (52 weeks). After completion of the
maintenance phase of the study, participants had the option to
continue/switch to the LA therapy for the duration of the
extension phase, which is ongoing. ATLAS participants also
had the option to rollover into the ongoing ATLAS-2M
randomized study (NCT03299049), comparing CAB + RPV
LA administered every 4 weeks vs every 8 weeks.20
ATLAS and FLAIR were conducted in accordance with
the Declaration of Helsinki.21 All participants provided
written informed consent. The study protocol, any amend-
ments, the informed consent, and other information that
required pre-approval were reviewed and approved by a
national, regional, or investigational center ethics committee
or institutional review board.
Endpoints and Assessments of
Pooled Analysis
The primary endpoint of this pooled analysis was the
proportion of participants with plasma HIV-1 RNA levels
$50 copies/mL at week 48 by FDA Snapshot algorithm. The
key secondary endpoint was the proportion of participants with
plasma HIV-1 RNA ,50 copies/mL at week 48. Selected
secondary and exploratory endpoints included virologic out-
comes by randomization strata and baseline subgroups,
resistance analysis of participants with CVF through week 48,
pharmacokinetic analysis, safety and tolerability, laboratory
abnormalities, and participant preference.
Statistical Methods and Populations
for Analysis
The planned participant number of 285 participants per
arm in each study was chosen to appropriately power the
statistical analyses of the primary and key secondary non-
inferiority endpoints of the individual studies. The overall
sample size provided sufficient power to perform the pooled
analysis. With the combined sample size of 570 participants
per treatment arm, the study would have 90% power to
demonstrate noninferiority for the primary endpoint of the
proportion of participants with virologic failure at week 48 by
the Snapshot intention-to-treat exposed (ITT-E) approach
using a prespecified 4% noninferiority margin. The ITT-E
population consisted of randomized participants who received
at least 1 dose of study drug during the maintenance phase of
the study (on or after day 1 visit). Participants were analyzed
according to the randomized treatment arm. The safety
population consisted of all randomized participants who
received at least 1 dose of study drug during the maintenance
phase of the study (on or after day 1 visit).
The primary and key secondary efficacy analyses were
based on the ITT-E population using the Snapshot algorithm.
For the primary analysis, treatment with CAB + RPV LA was
declared noninferior to CAR if the upper end limit of the
2-sided 95% confidence interval (CI) for the difference in
proportions of participants with plasma HIV-1 RNA
$50 copies/mL between the 2 groups [(CAB + RPV LA)—
CAR] at week 48 was less than 4%. For the key secondary
efficacy analysis, treatment with CAB + RPV LA was
declared noninferior to CAR if the lower limit of the
2-sided 95% CI for the difference in virologic suppression
rates (HIV-1 viral load ,50 copies/mL) between the 2 groups




A total of 1514 individuals were screened (ATLAS, n =
705; FLAIR, n = 809) and 1184 were randomized (2 participants
were randomized but did not receive treatment: 1 for non-
compliance with study treatment, 1 for noncompliance with
protocol procedures). Participant disposition is shown in Figure
1B. The baseline characteristics of participants in the LA and
CAR arms were similar (Table 1 and see Figure S1, Supple-
mental Digital Content, http://links.lww.com/QAI/B518). Over-
all, 591 participants in each arm initiated the maintenance phase
(n = 308 from ATLAS and n = 283 from FLAIR). Most
participants were of white race (LA, 73%; CAR, 69%), with a
median (range) age of 38 years (LA, 19–74 years; CAR,
18–82 years). Women accounted for.25% of participants (LA,
27%; CAR, 28%).
Efficacy
In the LA and CAR arms, 11 (2%) and 10 (2%)
participants, respectively, had HIV-1 RNA $50 copies/mL at
week 48, with an adjusted treatment difference [LA—CAR (95%
CI)] of 0.16% (21.35 to 1.67), meeting the noninferiority criteria
of the primary endpoint (4% noninferiority margin). The
secondary endpoint was also met, with 550 (93%) LA participants
and 558 (94%) CAR participants having HIV-1 RNA
,50 copies/mL at week 48, with an adjusted treatment difference
[LA—CAR (95% CI)] of 21.37% (24.12 to 1.39), meeting the
prespecified 210% noninferiority margin (Snapshot) (Table 2).
In the LA arm, 98% of the 6920 expected injection
visits across the 2 studies occurred within the allowed
67 days of the planned visit day. No participant who
received an injection outside of the allowable dosing window
met CVF criteria. In total, oral bridging ranging 4–61 days
was utilized in 16 participants to cover missed (n = 7) or
delayed (n = 9) injection visits.
Efficacy results were generally consistent between
subgroups (see Figures S2 and S3, Supplemental Digital
Content, http://links.lww.com/QAI/B518). However, a
slightly higher proportion of women (sex at birth) and
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participants with a body mass index $30 kg/m2 in the LA
arm had HIV-1 RNA $50 copies/mL at week 48, with a
difference in proportion (95% CI) of 2.49 (20.64 to 6.54) and
3.06 (22.54 to 9.72), respectively. Also, the LA arm was
favored by the African American subgroup for the proportion
of participants with HIV-1 RNA ,50 copies/mL at week 48
[difference in proportion (95% CI) of 6.86 (0.12 to 13.90)].
Resistance Analysis
At week 48, 7 participants in each arm had CVF (2
consecutive plasma HIV-1 RNA measurements
$200 copies/mL). This includes 1 participant in the LA
arm of FLAIR who temporarily discontinued the oral lead-
in dosing during a work-up for an apparent positive
pregnancy test that was later confirmed to be a false
positive result and, upon re-initiation, met the criteria for
CVF; this participant, however, never received LA injec-
tions and was withdrawn from the study.
Of the 6 participants in the LA arm who received CAB
+ RPV LA, NNRTI (n = 6) and/or INSTI (n = 4) resistance
mutations were present at the time of suspected virologic
failure (Table 3). Four of these participants had HIV-1
subtype A1, 1 had subtype A, and 1 had subtype AG at
baseline. Of the 6 participants, NNRTI (n = 2) resistance
mutations and the INSTI L74I polymorphism (n = 5) were
present at baseline; all retained full susceptibility to dolute-
gravir at suspected virologic failure timepoint (below clinical
cut-off of 4.0-fold change). The participant who met CVF
criteria during the oral lead-in phase had HIV-1 subtype AG
with no resistance mutations detected.
Pharmacokinetics
Mean plasma CAB and RPV concentrations were well
above their respective PA-IC90 (CAB PA-IC90, 0.166 mg/mL;
RPV PA-IC90, 12 ng/mL)19 during the maintenance phase. At
week 8, 4 weeks after the initial IM loading dose (initial
trough concentration), pooled geometric mean (95% CI)
plasma concentrations were 1.38 mg/mL (1.31 to 1.46) for
CAB and 39.88 ng/mL (38.05 to 41.80) for RPV, 8-fold and
3-fold above their respective PA-IC90. At week 48, geometric
mean (95% CI) plasma concentrations were 2.97 mg/mL (2.85
to 3.10) for CAB and 86.42 ng/mL (82.87 to 90.14) for RPV,
approximately 18-fold and 7-fold above their respective
PA-IC90 values and similar to those reported in the
TABLE 2. Pooled Efficacy Outcomes at Week 48: ITT-E Population
Outcome
LA, n = 591,
n (%)






HIV-1 RNA ,50 copies/mL at week 48* (key
secondary endpoint)
550 (93.1) 558 (94.4) 21.35 (24.11 to 1.41) 21.37 (24.12 to 1.39)
HIV-1 RNA $50 copies/mL at week 48* (primary
endpoint)
11 (1.9) 10 (1.7) 0.17 (21.34 to 1.68) 0.16 (21.35 to 1.67)
Data in window not below threshold 3 (0.5) 3 (0.5)
Discontinued for lack of efficacy 7 (1.2) 5 (0.8)
Discontinued for other reason while not below
threshold
1 (0.2) 2 (0.3)
Change in background therapy 0 0
No virologic data 30 (5.1) 23 (3.9)
Discontinued study because of AE or death† 19 (3.2) 7 (1.2)
Discontinued study for other reasons 11 (1.9) 16 (2.7)
On study but missing data in window 0 0
*Per FDA Snapshot algorithm; 4% and 210% noninferiority margins prespecified for primary and key secondary endpoints, respectively.
†One death occurred in the CAR arm because of a methamphetamine overdose (ATLAS). This was determined to be unrelated to study treatment.
‡In ATLAS, CAR = standard 3-drug oral ART regimen; in FLAIR, CAR = ABC/DTG/3TC (a non-abacavir–based backbone was administered for participants positive for
HLA-B*5701, and an alternative backbone was chosen for those intolerant to or who developed toxicity to any component of the backbone regimen).
§Difference = proportion on LA minus proportion on CAR.
║Based on Cochran–Mantel–Haenszel stratified analysis, adjusted for 10 strata.
3TC, lamivudine; ABC, abacavir; CAR, current antiretroviral therapy; DTG, dolutegravir.
TABLE 1. Pooled Participant Baseline Characteristics: ITT-E
Population
LA (n = 591) CAR (n = 591)
Median age, yr (range) 38 (19–74) 38 (18–82)
Age $50 yr, n (%) 99 (17) 125 (21)
Women (sex at birth), n (%) 162 (27) 168 (28)
Race, n (%)
White 430 (73) 408 (69)
Black or African American 109 (18) 133 (23)
Other 52 (9) 50 (8)*
Mean weight (SD), kg† 77 (15.30) 77 (16.98)
Median BMI (range), kg/m2† 25 (15–51) 25 (13–58)
BMI $30, (%)† 100 (17) 103 (17)
Median CD4+ cell count (IQR), cells/mm3 645 (487–824) 641 (480–821)
HIV-1–HCV co-infection, n (%)† 42 (7) 40 (7)
Baseline for FLAIR was day 1 (maintenance phase).
*Two participants’ data are missing.
†Collected at induction baseline (week 220) for FLAIR.
BMI, body mass index; CAR, current antiretroviral therapy; IQR, interquartile
range; HCV, hepatitis C.
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LATTE-2 study.19 Individual plasma CAB and RPV concen-
trations in participants with CVF at the time of failure were
below the population means but, for most participants, were
within the overall range of exposures for individuals who
maintained virologic suppression. CAB/RPV plasma concen-
trations of those with CVF are presented in the individual
ATLAS and FLAIR supplementary sections.14,15
Safety and Tolerability
Adverse events (AEs) through week 48 are presented in
Table 4. When excluding injection site reactions (ISRs), AEs
were reported by 86% (n = 506) and 75% (n = 444) of
participants in the LA and CAR arms, respectively. Most of
these were grade 1 or 2, with 7% (n = 44) and 6% (n = 35) of
participants in the LA and CAR arms, respectively, reporting
an AE of grade $3. Drug-related AEs (excluding ISRs)
occurred in 28% (n = 165) of participants in the LA arm
compared with 6% (n = 35) in the CAR arm. AEs leading to
withdrawal were reported for 22 (4%) participants in the LA
arm and 9 (2%) participants in the CAR arm (specific reasons
for withdrawal are listed in Table 4). Serious AEs were
similar in both arms. Two serious AE occurrences were
considered by investigators to be related to the study
treatment: right knee mono-arthritis in the LA arm and
suicidal ideation in the CAR arm. One death occurred during
the maintenance phase due to a methamphetamine overdose
(CAR arm). This was determined to be unrelated to study
treatment. AEs during the oral lead-in period occurred in 32%
(n = 187) of participants; the 3 most commonly occurring
were headache [3% (n = 17)], nasopharyngitis, and vitamin D
deficiency [both 3% (n = 16)]. Mean (SD) weight change at
week 48 from baseline was an increase of 2.34 kg (5.67) and
1.17 kg (5.22) in the LA and CAR arms, respectively.
Seventeen (3%) participants in the LA arm and 6 (1%)
participants in the CAR arm had alanine aminotransferase
elevations $3 times the upper limit of normal. Eleven (2%)
and 3 (,1%) participants in the LA and CAR arms,
respectively, met protocol-defined liver-related stopping cri-
teria. Of these, 7 were diagnosed with hepatitis A, 3 with
hepatitis B, 2 with hepatitis C, and 1 with hepatitis E; none
were considered to represent drug-induced liver injury. Other
laboratory evaluations were unremarkable.
Throughout the course of the maintenance phase,
14,682 injections were given to 581 participants. A total of
3663 ISRs were reported, accounting for 25% of all injections
administered across the study period, ,1% (n = 34) of which
were grade $3 (see Table S1, Supplemental Digital Content,
http://links.lww.com/QAI/B518). No grade 4 or 5 ISRs were
reported. Most ISRs (88%) resolved within 7 days (median 3
days). Injection site pain was the most common event,
reported with 21% (n = 3087) of injections, 1% of which
(n = 32) were grade 3. Nodule, induration, and swelling were
TABLE 3. Subtypes and Mutations in ATLAS and FLAIR*
Study
Sex at Birth, Country, HIV-1
Subtype (Day 1/SVF)
Baseline RAMs† Viral Load at SVF/CVF
(Copies/mL)
SVF Timepoint RAMs Drug Sensitivity at
SVF (Fold Change)§NNRTI INSTI‡ NNRTI INSTI‡
ATLAS W, Russia, A1/A E138E/A None 79,166/25,745 E138A None RPV (2.4)
CAB (0.8)
DTG (0.9)
W, France, AG/AG V108V/I, E138K None 695/258 V108I, E138K None RPV (3.7)
CAB (1.2)
DTG (1.0)
M, Russia, A/A1 None None 544/1841 E138E/K N155H RPV (6.5)
CAB (2.7)
DTG (1.2)
FLAIR║ W, Russia, A1/A1 None None 373/456 E138E/A/K/T Q148R RPV (7.1)
CAB (5.2)
DTG (1.0)
M, Russia, A1/A1¶ None None 287/299 K101E G140R RPV (2.6)
CAB (6. 7)
DTG (2.2)
W, Russia, A1/A None None 488/440 E138K Q148R RPV (1.0)
CAB (9.4)
DTG (1.1)
*In the CAR arm, there were 7 CVFs. In ATLAS, there were 4 CVFs in the CAR arm, 3 of whom had reverse transcriptase mutations (M184I; M184V + G190S; and M230M/I)
detected in HIV-1 RNA samples from 1 participant each, and 1 had no mutations. In FLAIR, there were 3 CVFs in the CAR arm, all without treatment-emergent resistance mutations or
phenotypic changes.
†Baseline genotype sequences were derived from peripheral blood mononuclear cell HIV-1 DNA in ATLAS and plasma HIV-1 RNA in FLAIR.
‡L74I was present in 5 out of 6 participants at baseline and at SVF timepoint. It is not considered an INSTI RAM by IAS–USA guidelines and has no impact on CAB activity.28
§Monogram biological cut-offs: RPV = 2.0, CAB = 2.5; Monogram clinical cut-off: DTG = 4.0.
║FLAIR had 1 participant who had oral CAB + RPV dosing interrupted because of a false-positive pregnancy test and, upon re-initiation of oral therapy, had SVF that was
confirmed.
¶INSTI genotype and INSTI phenotype could not be generated at SVF timepoint (week 28). Therefore, week 24 plasma was sent for virology analyses, shown here.
CAB, cabotegravir; CAR, current antiretroviral therapy; DTG, dolutegravir; RAM, resistance-associated mutation; RPV, rilpivirine; SVF, suspected virologic failure.
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other reported ISRs, occurring in 140 (,1%), 136 (,1%),
and 86 (,1%) of administered injections. Six (1%) partici-
pants discontinued treatment because of ISRs, comprising
injection site pain in all cases (Table 4) either alone or with
injection site nodule (n = 1) and/or injection site swelling
(n = 1). The incidence of ISRs was highest at week 4, with
ISRs experienced by 70% of participants. The incidence
decreased over the course of the 48 weeks, occurring in 16%
of participants at Week 48 (see Figure S4, Supplemental
Digital Content, http://links.lww.com/QAI/B518).
Rates of AEs in the LA arm were similar between
men and women (sex at birth), with any AEs and drug-
related AEs reported in 91% (n = 148) and 78% (n = 126)
of women, respectively, compared with 96% (n = 413) and
85% (n = 365) in men, respectively. Of those who received
at least 1 injection, ISRs were reported in 81%
(n = 128/159) of women and 86% (n = 361/422) of men.
Discontinuation because of ISRs was 1% (n = 2) in women
and ,1% (n = 4) in men.
Preference
At weeks 24 and 44, there was a significant increase
from baseline in treatment satisfaction of injectable therapy in
participants in the LA arm compared with the CAR arm (see
Figure S5, Supplemental Digital Content, http://links.lww.
com/QAI/B518). Of the participants who responded to the
preference survey, 98% (523/532) preferred the LA regimen.
DISCUSSION
The pooled results of the ATLAS and FLAIR studies
described here demonstrate that monthly IM injections of
CAB + RPV LA are noninferior to CAR in maintaining
HIV-1 virologic suppression in treatment-experienced partic-
ipants. The results of the primary and secondary endpoints
were generally similar between subgroups. The findings are
consistent with the individual results of the ATLAS and
FLAIR studies,14,15 with this analysis gaining increased
power because of the pooling of the data. The high proportion
of participants with virologic success (HIV-1 RNA
,50 copies/mL) with LA therapy at week 48 (93%) in this
analysis is similar to previous phase 3 noninferiority switch
studies such as SWORD-1 and -2.22
The number of participants with CVF in the LA arm
was low, occurring in 7 (1%) participants through week 48.
This proportion is comparable to other large switch studies,
which also reported incidences of#1%.22,23 Excluding the 1
participant who discontinued oral lead-in dosing because of
a false-positive pregnancy test, all of these participants had
NNRTI (n = 6) and/or INSTI (n = 4) resistance-associated
mutations at time of suspected virologic failure. All except 1
(ATLAS, subtype AG) of these participants were subtype
A1 or A. All but the ATLAS participant with subtype AG
had the polymorphism L74I. However, subsequent in vitro
investigations of viruses from those participants with CVF
in the FLAIR study compared the observed INSTI
resistance-associated mutations with or without the L74I
polymorphism, and concluded that subtype A1 or B did not
differ with respect to sensitivity to CAB.24 Despite the
presence of INSTI resistance-associated mutations, all
participants retained full susceptibility to dolutegravir and
5/6 were subsequently resuppressed on alternative ART
(HIV-1 RNA ,50 copies/mL).
Because of the small sample size of participants with
CVF, no definitive conclusions can be made on factors that
could have contributed to CVF. No single factor alone (eg,
sex at birth, body mass index, region, race, age, or prior
NNRTI use) seemed to drive Snapshot or CVF (Table 2; see
Figure S2, Supplemental Digital Content, http://links.lww.
com/QAI/B518; data on file). The roles of certain patient and
viral factors, such as pharmacokinetics, HIV-1 subtype, and
TABLE 4. Pooled Adverse Events Through Week 48
Event category, n (%) LA (n = 591) CAR (n = 591)
Any AE 561 (95%) 444 (75%)
Excluding ISRs 506 (86%) 444 (75%)
Any grade $3 AE* 63 (11%) 35 (6%)
Excluding ISRs 44 (7%) 35 (6%)
Any AEs leading to withdrawal† 22 (4%) 9 (2%)
Any SAE 24 (4%) 25 (4%)
SAEs related to study treatment
(excluding ISRs)‡
1 (,1%) 1 (,1%)
Any drug-related AE 490 (83%) 35 (6%)
Excluding ISRs 165 (28%) 35 (6%)
Any grade $3 drug-related AE* 28 (5%) 1 (,1%)
Excluding ISRs 8 (1%) 1 (,1%)
Any injection site pain§ 458 (79%) N/A
Grade $3 severity§ 21 (4%) N/A
Leading to withdrawal§ 6 (1%) N/A
Common AEs ($5% in either arm)
excluding ISRs
Nasopharyngitis 108 (18%) 88 (15%)
Headache 71 (12%) 38 (6%)
Upper respiratory tract infection 66 (11%) 52 (9%)
Diarrhea 52 (9%) 38 (6%)
Pyrexia 43 (7%) 13 (2%)
Back pain 40 (7%) 23 (4%)
Influenza 41 (7%) 34 (6%)
Vitamin D deficiency 31 (5%) 24 (4%)
Nausea 30 (5%) 16 (3%)
AEs of special interest
Anxiety 27 (5%) 20 (3%)
Depression 16 (3%) 14 (2%)
Suicidal ideation/behavior 4 (,1%) 5 (,1%)
*There was only 1 (,1%) participant with a grade 5 AE (death) in the CAR arm
during the maintenance phase, which was due to a methamphetamine overdose that was
determined to be unrelated to study treatment.
†AEs leading to withdrawal in .1 participant in the LA arm were injection site pain
(n = 6); hepatitis (hepatitis A, n = 4; acute hepatitis B and C, n = 3 and n = 1,
respectively); headache (n = 2); and diarrhea (n = 2). No single AE leading to
withdrawal was reported in .1 participant in the CAR arm.
‡Serious AEs related to study treatment: LA arm, right knee mono-arthritis; CAR
arm, suicidal ideation.
§Percentages based on number of participants who received at least 1 injection (n =
581).
CAR, current antiretroviral therapy; SAE, serious AE.
Rizzardini et al J Acquir Immune Defic Syndr  Volume 85, Number 4, December 1, 2020
504 | www.jaids.com Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
L74I polymorphism, are being evaluated to further define
their contributions toward virologic failure development.
Overall, excluding ISRs, the observed AE profile with
CAB + RPV LA therapy was similar to that in the CAR arm
and is in line with the previously reported safety profile of
CAB + RPV oral therapy.16 Despite ISRs being common (25%
of administered injections), most were mild (99% grade 1 or 2).
Overall incidence of ISRs steadily decreased throughout the
study (week 4, 70%; week 48, 16%) and the duration of ISRs
was short (median 3 days). These data suggest the initial high
incidence of ISRs may have been because of initiation of a
novel treatment administration route (IM injection), with a
reduced incidence over the longer term as participants became
more familiar with the injection procedure.
Both studies enrolled a substantial number of women
(sex at birth) [ITT-E populations: ATLAS, 33% (n = 203);
FLAIR, 22% (n = 127)], exceeding that targeted for inclusion
in the individual studies (25% in ATLAS, 20% in FLAIR).
This is an important achievement given that women are often
under-represented in ART clinical trials,25 despite accounting
for the majority of adults living with HIV globally (WHO
estimates, 2018).1,2 In this analysis, efficacy was comparable
between men and women.
In the era of highly active ART, developing therapies
that cause minimal disruption to the daily lives of PLWH is a
key goal of current research efforts. Along with reducing
exposure to the number of ART agents compared with
traditional 3-drug regimens, CAB + RPV LA reduces the
dosing frequency from daily to monthly. Some populations of
PLWH may therefore find this a preferable option to their daily
CAR, potentially facilitating improved adherence in those who
report factors such as pill burden and forgetfulness as barriers
to adherence.4 The Positive Perspectives study involving over
1000 PLWH found that most regarded daily ART as a
“reminder of their HIV status,” whereas 25% felt “being tied
to daily medication limited their day to day life.”7 Monthly
CAB + RPV LA injections may therefore represent a more
discreet regimen that could help some PLWH avoid the stigma
associated with their HIV status. CAB + RPV LA would also
enable the first option for directly observed therapy because of
the monthly clinic visits required. This would result in more
frequent interactions with health care professionals, which
could potentially improve retention in care. Therefore, CAB +
RPV LA may be a welcome treatment option for such
populations of PLWH who are virally suppressed and see
monthly injections as a beneficial trade-off for freedom from
daily ART; however, the impact of monthly visits on HIV
clinics will need to be considered.
Further to CAB + RPV LA being a welcomed treatment
option compared with daily ART, nearly all of the partici-
pants who completed the preference question preferred the
LA regimen over the oral regimen (98%). This is consistent
with findings from the LATTE-2 study, in which participants
also reported a preference for CAB + RPV LA therapy
compared with daily oral ART.26
Although the reduced dosing frequency of CAB + RPV
LA may be beneficial to some PLWH, this needs to be
specifically assessed in different populations, particularly those
with adherence challenges. LATITUDE (NCT03635788), a
study investigating CAB + RPV LA in PLWH with a history
of suboptimal adherence, will provide further clarity in this
regard.27 In addition, the present analysis is limited by the
relatively short duration of treatment (48 weeks). Longer-
term data will be provided by the 96-week results. In
addition, there was likely a selection bias with the ATLAS
and FLAIR studies, whereby only PLWH who were
interested in an LA IM injectable regimen were likely to
enroll. However, CAB + RPV LA is intended to add a
novel therapy option to the treatment armamentarium for
those willing to receive injections who may benefit from
reduced dosing frequency.
In summary, the once-monthly regimen of CAB + RPV
LA was noninferior to CAR in maintaining HIV-1 suppres-
sion in individuals with a prior treatment history of 20 weeks
to many years of suppressive ART. These efficacy and safety
results indicate CAB + RPV LA can be a potential therapeutic
approach for virologically suppressed PLWH-1.
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